Literature DB >> 3281972

Quality of commercially produced Shigella serogrouping and serotyping antisera.

G M Evins1, L L Gheesling, R V Tauxe.   

Abstract

Shigella grouping antisera from five manufacturers and typing antisera from two were purchased and evaluated with homologous and heterologous Shigella strains in the slide agglutination test. Only 31 of 73 (42%) antisera were satisfactory. In many instances, the antisera gave negative, as opposed to weak, reactions when they should have given strong positive reactions. Four reagents cross-reacted with Shigella strains. Of the 19 polyvalent grouping antisera to subgroups Shigella dysenteriae serotypes 1 through 7, S. flexneri serotypes 1 through 6, S. boydii serotypes 1 through 7, and S. sonnei forms I, II, only one S. sonnei reagent and five S. flexneri reagents were satisfactory with greater than or equal to 90% of the homologous strains. The reagent of poorest quality was satisfactory with only 18% of the homologous strains. There were three polyvalent antisera to the higher types of S. dysenteriae and S. boydii, which were available from only one company, that adequately identified 80, 63, and 65% of the homologous strains. Typing antisera were available from only two companies, and 30 of 51 (59%) were satisfactory. Commercially available Shigella antisera are inadequate for the laboratory testing required for planning the development of and evaluating Shigella vaccines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281972      PMCID: PMC266309          DOI: 10.1128/jcm.26.3.438-442.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to type I and type III:6,7,8 antigens, group 6 antigen, and a core epitope.

Authors:  N I Carlin; A A Lindberg
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

2.  Shigella flexneri O-antigen epitopes: chemical and immunochemical analyses reveal that epitopes of type III and group 6 antigens are identical.

Authors:  N I Carlin; T Wehler; A A Lindberg
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

Review 3.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

4.  Secretory immunoglobulin A response following peroral priming and challenge with Shigella flexneri lacking the 140-megadalton virulence plasmid.

Authors:  D F Keren; R A McDonald; S B Formal
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

5.  Structural studies of Shigella flexneri O-antigens.

Authors:  L Kenne; B Lindberg; K Petersson; E Katzenellenbogen; E Romanowska
Journal:  Eur J Biochem       Date:  1978-11-02

6.  Structural studies of the Shigella flexneri variant X, type 5 a and type 5 b O-antigens.

Authors:  L Kenne; B Lindberg; K Petersson; E Katzenellenbogen; E Romanowska
Journal:  Eur J Biochem       Date:  1977-06-15

7.  Monoclonal antibodies specific for O-antigenic polysaccharides of Shigella flexneri: clones binding to II, II:3,4, and 7,8 epitopes.

Authors:  N I Carlin; A A Lindberg
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

8.  Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence.

Authors:  P J Sansonetti; D J Kopecko; S B Formal
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

9.  Involvement of a plasmid in the invasive ability of Shigella flexneri.

Authors:  P J Sansonetti; D J Kopecko; S B Formal
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

10.  Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp.

Authors:  E V Oaks; T L Hale; S B Formal
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

View more
  7 in total

1.  Serological cross-reactivity of environmental isolates of Enterobacter, Escherichia, Stenotrophomonas, and Aerococcus with Shigella spp.-specific antisera.

Authors:  Mohammed Ziaur Rahman; Munawar Sultana; Sirajul Islam Khan; Nils-Kåre Birkeland
Journal:  Curr Microbiol       Date:  2006-12-13       Impact factor: 2.188

2.  Evaluation of commercial antisera for Shigella serogrouping.

Authors:  J Lefebvre; F Gosselin; J Ismaïl; M Lorange; H Lior; D Woodward
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

Review 3.  Shigellemia in AIDS patients: case report and review of the literature.

Authors:  J Huebner; W Czerwenka; E Gruner; A von Graevenitz
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

4.  Use of monoclonal antibodies to type Shigella flexneri in Bangladesh.

Authors:  N I Carlin; M Rahman; D A Sack; A Zaman; B Kay; A A Lindberg
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

5.  Differentiation of Shigella flexneri strains by rRNA gene restriction patterns.

Authors:  S M Faruque; K Haider; M M Rahman; A R Abdul Alim; Q S Ahmad; M J Albert; R B Sack
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 6.  Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005.

Authors:  P K Ram; J A Crump; S K Gupta; M A Miller; E D Mintz
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

7.  Monoclonal antibodies for detection of the H7 antigen of Escherichia coli.

Authors:  Y He; J E Keen; R B Westerman; E T Littledike; J Kwang
Journal:  Appl Environ Microbiol       Date:  1996-09       Impact factor: 4.792

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.